Study of Kesimpta in Greek MS Patients
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study watches how well Kesimpta (ofatumumab) works for people with relapsing multiple sclerosis over time. It collects information from routine doctor visits and scans to see if the treatment is controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of relapsing multiple sclerosis (RMS) based on 2017 McDonald criteria.
- Your first MS symptoms started less than 5 years ago.
- You have been taking Kesimpta for at least 3 months but no longer than 6 months.
- You have had a brain MRI scan at least 3 months after starting Kesimpta, or your doctor plans to do one within 31 days after you join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
This registry collects information about pregnancy outcomes in people with multiple sclerosis (MS) who have taken Kesimpta (ofatumumab) during pregnancy or shortly before it. It may help doctors better understand safety and developmental outcomes for babies.
This study looks at the safety of Kesimpta (a multiple sclerosis medication) during pregnancy. It compares outcomes for women who took Kesimpta or other MS drugs while pregnant to those who did not.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Hear when a new Relapsing Multiple Sclerosis (RMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.